28 results on '"Haeussler, B."'
Search Results
2. Weak lensing studies from space with GEMS
3. PHP71 - Impact of the Early Benefit Assessment on A Pharmaceutical's Real Consumption in Germany
4. PCN171 - Quality of Life (QOL) During Treatment of Newly Diagnosed Locally Confined Low-Risk Prostate Cancer (LCLRPC) in Germany: Results of the Harow Study
5. PCN136 - Cost-Utility Analysis (CUA) of Different Strategies to Treat Newly Diagnosed Locally Confined Low-Risk Prostate Cancer (LCLRPC) in Germany: Results of the Harow Study
6. PCN129 - Cost-Minimization Analysis (CMA) of Different Strategies to Treat Newly Diagnosed Locally Confined Low-Risk Prostate Cancer (LCLRPC) in Germany: Results of the Harow Study
7. PHP153 Supporting Payers with Collaborative HTA Tools in Making Evidence-Based Decisions: The United States Experience and International Needs in Europe and Globally
8. PDB60 HEALTH ECONOMIC EVALUATIONS COMPARING THE BASAL INSULIN ANALOGUES INSULIN GLARGINE (GLA) AND INSULIN DETEMIR (DET) IN INTENSIFIED INSULIN THERAPY (ICT) IN PATIENTS WITH TYPE 1 DIABETES: A SYSTEMATIC REVIEW
9. PDB59 HEALTH ECONOMIC EVALUATIONS COMPARING THE BASAL INSULIN ANALOGUE GLARGINE (GLA) WITH NEUTRAL PROTAMINE HAGEDORN (NPH) INSULIN IN INTENSIFIED INSULIN THERAPY (ICT) IN PATIENTS WITH TYPE 1 DIABETES:A SYSTEMATIC REVIEW
10. PDB54 COMPARISON OF TREATMENT COSTS BETWEEN BASAL-SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE (GLA) AND BOT WITH INSULIN DETEMIR (DET) IN PATIENTS WITH TYPE 2 DIABETES (T2D): ECONOMIC EVALUATION BASED ON THE RESULTS OF THE INSULIN GLARGINE (LANTUS®) VERSUS INSULIN DETEMIR (LEVEMIR®) TREAT-TO-TARGET (L2T3) STUDY
11. PMH2 EVIDENCE FOR SSRI IN THE TREATMENT OF DEPRESSION: EARLY KNOWLEDGE GAIN—LATE CONSEQUENCES IN ROUTINE CARE?
12. ANALYSIS OF HORMONE THERAPY PRESCRIPTION RATES BEFORE AND AFTER THE WHI STUDY USING CLAIMS DATA OF A GERMAN SICKNESS FUND
13. PMH54 INDICATION SPECTRUM OF SNRI APPLIED FOR THE TREATMENT OF DEPRESSION—A PHARMACOEPIDEMIOLOGICAL ANALYSIS OF CLAIMS DATA OF A GERMAN SICKNESS FUND
14. PMS67 HEALTH GAINS FOREGONE DUETO THE SUSTAINED DELAY OF ADEQUATE UTILIZATION OF EVIDENCE BASED TREATMENTS: THE CASE OF BISPHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS
15. PHP30 COST DRIVERS IN THE PHARMACEUTICAL MARKET IN GERMANY IN 2007
16. PHP3 INNOVATIVE HEALTHTECHNOLOGIES IN THE “ANTI-AGING-MEDICINE” FIELD: RESULTS FROM A SYSTEMATIC HORIZON SCANNING
17. PAR10 MANAGEMENT OF RHEUMATOID ARTHRITIS—FINDINGS FORM A CLAIMS DATABASE ANALYSIS
18. Oral bisphosphonates are associated with low persistence and compliance (adherence) in patients with breast cancer
19. POB4 USING CLAIMS DATA TO UNDERSTAND THE COSTS OF DIFFERENT HEALTH STATES FOR PATIENTS WITH CARDIOMETABOLIC RISK
20. PMH18 DIRECT COST OF DEPRESSION–ANALYSIS OF A GERMAN CLAIMS DATABASE
21. PRS1 PREVALENCE AND TREATMENT OF COPD IN GERMANY
22. GI2 DICLOFENAC-ASSOCIATED ULCER RISK IS REDUCED BY PROTON PUMP INHIBITORS: NESTED CASE CONTROL STUDY
23. Low persistency with oral bisphosphonates in cancer patients
24. PRS2 PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN SICKNESS FUND POPULATION
25. PCV66 PATIENTS ON ARBS (AND VALSARTAN AS A REPRESENTATIVE) EXPERIENCE HIGHER PERSISTENCE AND COMPLIANCE (ADHERENCE) WITH THERAPY COMPARED TO OTHER ANTIHYPERTENSIVE CLASSES IN A GERMAN SICKNESS FUND POPULATION
26. PUK8 2-HOUR POST DOSE (C2) MONITORING VERSUS TROUGH (C0) MONITORING OF NEORAL: AN ECONOMIC EVALUATION
27. PDB5 COMMUNITY EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS IN GERMANY
28. PMD30 MODELLING OF PREVALENCE, COSTS AND OUTCOME OF ACID-RELATED DISORDERS USING CLAIMS DATA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.